drugset / Trial / NCT05352867
Clinical Trial of SARS-CoV-2 mRNA Vaccine in Chinese People
Phase 2
Completed
420 enrolled
AIM Vaccine Co., Ltd.
Hunan Provincial Center for Disease Control and Prevention · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
Phase Ⅱ Clinical Trial to Evaluate the Safety and Immunogenicity of the New Coronavirus mRNA Vaccine (LVRNA009) in Chinese People Aged 18\~59 Years
Timeline
- Start
- 2022-03-16
- Primary completion
- 2022-06-23
- Completion
- 2023-06-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LVRNA009 | Messenger RNA (mRNA) | 50 ug | — |
| Subject | LVRNA009 | Messenger RNA (mRNA) | 100 ug | — |